Evidence map›Paper›PMID 38227614›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Cardiovascular Disease Risk Factor Control in People With and Without HIV.

Michael J Silverberg, Tory M Levine, Alexandra N Lea, Andrew E Williams, Stacey E Alexeeff, Kendall Bryant, Matthias Cavassini, Jason A Flamm, C Bradley Hare, Suzanne M Ingle and 5 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael J SilverbergDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.ORCID 0000-0001-9322-1395
Tory M LevineDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Alexandra N LeaDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Andrew E WilliamsInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.
Stacey E AlexeeffDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Kendall BryantNational Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA.
Matthias CavassiniLausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Jason A FlammKaiser Permanente Sacramento Medical Center, Sacramento, California, USA.
C Bradley HareKaiser Permanente SanFrancisco Medical Center, San Francisco, California, USA.
Suzanne M InglePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Amy C JusticeVA Connecticut Healthcare System, Yale University Schools of Medicine and Public Health, New Haven, Connecticut, USA.
Jennifer O LamDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Stacy A SterlingDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Michael A HorbergKaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, Maryland, USA.
Derek D SatreDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
2/3 COMpAAAS Tripartite: ART-CC, KP, and VAU01AA026230 · NIAAA · KAISER FOUNDATION RESEARCH INSTITUTE · PI SATRE, DEREK D, SILVERBERG, MICHAEL J · 2017 to 2021
$3.0M
3/3 COMpAAAS Tripartite: ART-CC, KP, and VAU01AA026224 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2017 to 2021
$2.9M
1/3 Collaborative Research in HIV/AIDS, Alcohol, and Related Comorbidities (COMpAAAS) Tripartite: ART-CC, KP, and VAU01AA026209 · NIAAA · UNIVERSITY OF BRISTOL · PI STERNE, JONATHAN · 2017 to 2021
$2.2M
Mentoring alcohol use intervention research in HIV health care settingsK24AA025703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Derek D Satre · 2018 to 2026
$1.8M
Electronic Health Record-Based Dementia Prediction for HIV Primary CareK01AI157849 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI LAM, JENNIFER · 2021 to 2025
$713k
NCATS NIH HHS UL1 TR001863NIAAA NIH HHS K24 AA025703NIAAA NIH HHS U01 AA026209NIAAA NIH HHS U01 AA026224NIAAA NIH HHS U01 AA026230NIAID NIH HHS K01 AI157849
6 · The paper itself

Abstract

backgroundManagement of hypertension, dyslipidemia, diabetes and other modifiable factors may mitigate the cardiovascular disease (CVD) risk in people with human immunodeficiency virus (HIV, PWH) compared with people without HIV (PWoH).

methodsThis was a retrospective cohort study of 8285 PWH and 170 517 PWoH from an integrated health system. Risk factor control was measured using a novel disease management index (DMI) accounting for amount/duration above treatment goals (0% to 100% [perfect control]), including 2 DMIs for hypertension (diastolic and systolic blood pressure), 3 for dyslipidemia (low-density lipoprotein, total cholesterol, triglycerides), and 1 for diabetes (HbA1c). CVD risk by HIV status was evaluated overall and in subgroups defined by DMIs, smoking, alcohol use, and overweight/obesity in adjusted Cox proportional hazards models.

resultsPWH and PWoH had similar DMIs (80%-100%) except for triglycerides (worse for PWH) and HbA1c (better for PWH). In adjusted models, PWH had an elevated risk of CVD compared with PWoH (hazard ratio [HR], 1.18; 95% confidence interval [CI], 1.07-1.31). This association was attenuated in subgroups with controlled dyslipidemia and diabetes but remained elevated for PWH with controlled hypertension or higher total cholesterol. The strongest HIV status association with CVD was seen in the subgroup with frequent unhealthy alcohol use (HR, 2.13; 95% CI, 1.04-4.34).

conclusionsControl of dyslipidemia and diabetes, but not hypertension, attenuated the HIV status association with CVD. The strong association of HIV and CVD with frequent unhealthy alcohol use suggests enhanced screening and treatment of alcohol problems in PWH is warranted.

Indexed as

Cardiovascular DiseasesHIV InfectionsAdultAgedDiabetes MellitusDyslipidemiasFemaleHeart Disease Risk FactorsHumansHypertensionMaleMiddle AgedRetrospective StudiesRisk Factorscardiovascular diseasediabetesdyslipidemiaHIVhypertension

Identifiers

PMID38227614
PMCPMC11093675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.